” But the Marin-based start-up that is out to pursue that approach faces long odds for success.

  Beyond their initial focus on osteoarthritis, Unity Biotechnology co-founder Judith Campisi anticipates that their approach of selectively eliminating senescent cells can eventually be applied to a broad array of maladies associated with aging.

Because of their complexity, Alzheimer’s and Parkinson’s lie at the high-risk end of that spectrum, adds CEO Nathaniel David, whereas chronic kidney disease is closer to the midpoint.

Original Source